Physician profile
Christopher David Liedke
NPI 1982022943
$14,881.11
in general payments reported to CMS, 2019-2025
29 companies · $4,133 in 2025
The $4,133 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $25.25 · 2021: $1,241 · 2022: $1,659 · 2023: $2,502 · 2024: $5,320 · 2025: $4,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,895 · Consulting Fee: $3,605 · Education: $350 · Travel and Lodging: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,894.65 |
| Consulting Fee | $3,605.00 |
| Education | $349.96 |
| Travel and Lodging | $105.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,892.19 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $2,044.18 | 2021-2025 | Tavneos, Krystexxa, Uplizna |
| Abbvie INC. | $1,924.89 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $1,220.36 | 2024-2025 | Strensiq |
| Pfizer INC. | $1,200.11 | 2021-2025 | |
| Biogen, INC. | $854.51 | 2021-2024 | Vumerity, Tysabri |
| E.R. Squibb & Sons, L.L.C. | $605.23 | 2021-2025 | Zeposia |
| Tg Therapeutics, INC. | $392.16 | 2023-2025 | |
| Emd Serono, INC. | $364.73 | 2023-2024 | Mavenclad |
| Glaxosmithkline, LLC. | $325.87 | 2021-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $276.04 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $219.50 | 2022-2025 | Tymlos |
| Ucb, INC. | $218.82 | 2023-2025 | Bimzelx, Cimzia |
| Genentech USA, INC. | $199.54 | 2024-2025 | Ocrevus, Enspryng |
| Lilly USA, LLC | $179.59 | 2022-2024 | Taltz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $151.53 | 2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $126.85 | 2022 | |
| Lundbeck LLC | $124.99 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $117.35 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $114.26 | 2022 | |
| Ani Pharmaceuticals, INC. | $72.03 | 2025 | Purified Cortrophin Gel |
| Sandoz INC. | $54.61 | 2023-2024 | Hyrimoz |
| Horizon Therapeutics Plc | $39.86 | 2022-2023 | Krystexxa |
| Harmony Biosciences LLC | $39.33 | 2024 | |
| Aurinia Pharma U.S., INC. | $36.10 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $28.36 | 2022 | |
| Octapharma USA, INC. | $23.02 | 2023 | Octagam Immune Globulin (Human) |
| Jazz Pharmaceuticals INC. | $22.32 | 2022 | |
| Merck Sharp & Dohme LLC | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Liedke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.